Tags

Type your tag names separated by a space and hit enter

Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial.
Eur Neuropsychopharmacol 2013; 23(7):636-44EN

Abstract

Controversy exists as to whether eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) or both are responsible for the efficacy of n-3 polyunsaturated fatty acids in depression. We conducted a single-center, randomized, double-blind, placebo-controlled, multi-arm, parallel-group trial, comparing the efficacy of EPA versus DHA as adjuvants to maintenance medication treatments for mild-to-moderate depression. Eighty-one mild-to-moderately depressed outpatients were randomly assigned to receive either 1g/d of EPA or DHA or placebo (coconut oil) for 12 weeks. The primary outcome measure was the 17-item Hamilton Depression Rating Scale (HDRS) final score in the modified intention-to-treat population, which comprised of all randomized patients with at least 1 post-randomization observation (n=62; 61.3% female; mean age 35.1 ± 1.2 years). Allocated treatments were well tolerated. Although there was no significant difference between groups at baseline, patients in the EPA group showed a significantly lower mean HDRS score at study endpoint compared with those in the DHA (p<0.001) or placebo (p=0.002) groups. Furthermore, response to treatment (defined as a ≥ 50% decrease from the baseline HDRS score) was only observed in 6 patients receiving EPA, while no one in any of DHA or placebo groups responded to treatment. Overall, these data suggest greater efficacy of EPA compared to DHA or placebo as an adjunctive treatment in mild-to-moderate depression. However, further, randomized controlled trials are needed to support these findings.

Authors+Show Affiliations

Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22910528

Citation

Mozaffari-Khosravi, Hassan, et al. "Eicosapentaenoic Acid Versus Docosahexaenoic Acid in Mild-to-moderate Depression: a Randomized, Double-blind, Placebo-controlled Trial." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 23, no. 7, 2013, pp. 636-44.
Mozaffari-Khosravi H, Yassini-Ardakani M, Karamati M, et al. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2013;23(7):636-44.
Mozaffari-Khosravi, H., Yassini-Ardakani, M., Karamati, M., & Shariati-Bafghi, S. E. (2013). Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 23(7), pp. 636-44. doi:10.1016/j.euroneuro.2012.08.003.
Mozaffari-Khosravi H, et al. Eicosapentaenoic Acid Versus Docosahexaenoic Acid in Mild-to-moderate Depression: a Randomized, Double-blind, Placebo-controlled Trial. Eur Neuropsychopharmacol. 2013;23(7):636-44. PubMed PMID: 22910528.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. AU - Mozaffari-Khosravi,Hassan, AU - Yassini-Ardakani,Mojtaba, AU - Karamati,Mohsen, AU - Shariati-Bafghi,Seyedeh-Elaheh, Y1 - 2012/08/19/ PY - 2012/05/01/received PY - 2012/07/23/revised PY - 2012/08/02/accepted PY - 2012/8/23/entrez PY - 2012/8/23/pubmed PY - 2014/1/24/medline SP - 636 EP - 44 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 23 IS - 7 N2 - Controversy exists as to whether eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) or both are responsible for the efficacy of n-3 polyunsaturated fatty acids in depression. We conducted a single-center, randomized, double-blind, placebo-controlled, multi-arm, parallel-group trial, comparing the efficacy of EPA versus DHA as adjuvants to maintenance medication treatments for mild-to-moderate depression. Eighty-one mild-to-moderately depressed outpatients were randomly assigned to receive either 1g/d of EPA or DHA or placebo (coconut oil) for 12 weeks. The primary outcome measure was the 17-item Hamilton Depression Rating Scale (HDRS) final score in the modified intention-to-treat population, which comprised of all randomized patients with at least 1 post-randomization observation (n=62; 61.3% female; mean age 35.1 ± 1.2 years). Allocated treatments were well tolerated. Although there was no significant difference between groups at baseline, patients in the EPA group showed a significantly lower mean HDRS score at study endpoint compared with those in the DHA (p<0.001) or placebo (p=0.002) groups. Furthermore, response to treatment (defined as a ≥ 50% decrease from the baseline HDRS score) was only observed in 6 patients receiving EPA, while no one in any of DHA or placebo groups responded to treatment. Overall, these data suggest greater efficacy of EPA compared to DHA or placebo as an adjunctive treatment in mild-to-moderate depression. However, further, randomized controlled trials are needed to support these findings. SN - 1873-7862 UR - https://www.unboundmedicine.com/medline/citation/22910528/Eicosapentaenoic_acid_versus_docosahexaenoic_acid_in_mild_to_moderate_depression:_a_randomized_double_blind_placebo_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-977X(12)00221-0 DB - PRIME DP - Unbound Medicine ER -